InsidersTradesSigma
Follow the Crinetics Pharmaceuticals, Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Crinetics Pharmaceuticals, Inc. has logged 208 reports. Market capitalisation: €9bn. The latest transaction was reported on 24 August 2026 (Attribution). Among the most active insiders: Betz Stephen F.. Every trade is openly available.
208
Insider Decl.
n/a
Thresholds
€24m
3 ops.
Buy Volume
€14m
70 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Crinetics Pharmaceuticals, Inc. Hold (neutral), based on 10 analysts. Average price target: US$85.50.
55Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 21,219 of 29,055 companies
36.2
score / 100
Value22
Quality50
FCF yld-4.3%
Earn yld-5.2%
EV/EBITDA·
ROE-42%
Gross mgn86%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 24 August 2026
Declarations208 total
471 shares0Common StockSEC:0001628280-26-058664:0
4,422 shares@ US$22.610.0011% mcap1.3% of flowCommon StockSEC:0001628280-26-055700:1
6,542 shares@ US$15.290.0011% mcap1.3% of flowCommon StockSEC:0001628280-26-055700:2
4,995 shares@ US$20.020.0011% mcap1.3% of flowCommon StockSEC:0001628280-26-055700:3
3,969 shares@ US$25.190.0011% mcap1.3% of flowCommon StockSEC:0001628280-26-055700:0
3,000 shares@ US$40.000.0014% mcap50.7% of flowCommon StockSEC:0001628280-26-047507:0
6,000 shares@ US$38.680.0026% mcap100.0% of flowCommonSEC144:0001950047-26-006823
47,420 shares@ US$38.680.021% mcap100.0% of flowCommonSEC144:0001950047-26-006832
5,925 sharesCommon StockSEC:0001628280-26-044712:0
5,925 sharesCommon StockSEC:0001628280-26-044708:0
5,925 sharesCommon StockSEC:0001628280-26-044710:0
5,925 sharesCommon StockSEC:0001628280-26-044714:0
5,925 sharesCommon StockSEC:0001628280-26-044715:0
5,925 sharesCommon StockSEC:0001628280-26-044717:0
5,925 sharesCommon StockSEC:0001628280-26-044721:0
6,292 sharesCommon StockSEC:0001628280-26-044419:0
608 sharesCommon StockSEC:0001628280-26-044419:1
6,900 shares@ US$35.000.0027% mcap100.0% of flowCommonSEC144:0001950047-26-006257
85,163 shares@ US$40.1049.3% of flowCommon StockSEC:0001628280-26-024716:3
49,474 shares@ US$23.9817.1% of flowCommon StockSEC:0001628280-26-024716:0
9,624 shares@ US$20.022.8% of flowCommon StockSEC:0001628280-26-024716:1
19,336 shares@ US$19.645.5% of flowCommon StockSEC:0001628280-26-024716:2
5,950 shares@ US$37.113.1% of flowCommon StockSEC:0001628280-26-019503:0
6,371 shares@ US$37.114.2% of flowCommon StockSEC:0001628280-26-019498:0
13,196 shares@ US$37.116.7% of flowCommon StockSEC:0001628280-26-019488:0
25 of 208 declarations
关于 Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) 是一家总部位于美国加利福尼亚州圣迭戈的美国生物制药公司。该公司由在内分泌药物发现方面拥有丰富经验的科学家于2008年创立，其业务围绕内部发现的用于内分泌疾病和内分泌相关肿瘤的小分子疗法。随着时间的推移，Crinetics 已从一家临床阶段开发商发展成为一家拥有商业资产的公司，同时仍保持广泛的研发管线。([sec.gov](https://www.sec.gov/Archives/edgar/data/1658247/000095017025057467/crnx_ars_2024.pdf?utm_source=openai)) Crinetics 的核心业务专注于精准内分泌学。该公司开发口服、非肽类疗法，旨在针对重要的激素受体通路，项目涵盖垂体疾病、肾上腺疾病和选定的神经内分泌肿瘤。其主要产品 PALSONIFY™ (paltusotine) 在2025年9月获得 FDA 批准用于成人肢端肥大症，成为该公司首个获批并商业化的疗法，达到了一个重要的转折点。管理层还披露了10多个项目的管线，包括正在开发用于先天性肾上腺增生和 ACTH 依赖性库欣综合征的 atumelnant，以及用于 SST2 表达肿瘤的非肽类药物偶联物 CRN09682。([crinetics.com](https://crinetics.com/crinetics-announces-fda-approval-of-palsonify-paltusotine-for-the-treatment-of-acromegaly-in-adults/?utm_source=openai)) 从竞争角度来看，Crinetics 定位为利基内分泌专家，拥有差异化的科学平台，并高度专注于治疗选择有限的疾病。这种专业化在生物技术领域具有吸引力，因为它支持深厚的临床专业知识、在罕见病市场中潜在的显著定价权，以及在目标患者群体中更清晰的商业化路径。该公司还披露了 Crinetics Pharmaceuticals Europe GmbH 的成立，这表明其正在逐步努力支持美国以外的开发、监管和商业化前活动。([ir.crinetics.com](https://ir.crinetics.com/news/news-details/2024/EY-ANNOUNCES-SCOTT-STRUTHERS-PH-D--CEO-AND-FOUNDER-OF-CRINETICS-PHARMACEUTICALS-AS-AN-ENTREPRENEUR-OF-THE-YEAR-2024-PACIFIC-SOUTHWEST-AWARD-WINNER-06-18-2024/default.aspx?utm_source=openai)) 公司近期更新强调了业务转型。在2025年和2026年期间，Crinetics 报告了 PALSONIFY 的持续上市执行、atumelnant 在临床开发中的进一步进展，以及 CAH 和其他内分泌适应症后期项目的进展。该公司还在2026年完成了一次公开发行股票，以支持商业上市活动和研发，强化了其资本密集型特征。对于法国、比利时和瑞士的投资者而言，CRNX 因此是一家在纳斯达克上市的美国医疗保健公司，兼具商业潜力与典型的生物技术风险，包括监管执行、临床结果、制造依赖性和资金需求。([crinetics.com](https://crinetics.com/press-releases/crinetics-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-business-update/?utm_source=openai))
